Table of Contents
There are over 2,000 cell and gene therapy clinical trials underway worldwide, in a market on track to hit $33 billion by 2032.
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
The International Society for Cell & Gene Therapy (ISCT) is the global body steering that translation, leading evidence-based standards across the field. President Miguel Forte, who took the chair in June 2024 and was named to The Medicine Maker's 2025 Advanced Medicine Power List, is steering ISCT through one of the toughest funding climates the sector has ever seen. He also runs Kiji Therapeutics, where lead candidate KJ01 – gene-engineered mesenchymal stem cells designed to boost regulatory T-cell activity – is moving toward first-in-human trials in acute graft-versus-host disease.
At Advanced Therapies 2026, Onyx sat down with the President of the International Society for Cell & Gene Therapy, Miguel Forte, to find out more.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments